부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
R&D news | Bukwang Pharmaceutical increased the number of patients for ..
Bukwang increased the number of patients from 40 to 80Bukwang announced that the..
2021.04.13
R&D news | Bukwang received US FDA approval for phase 2 clinical study ..
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced that they received US FDA..
2021.02.05
R&D news | Bukwang concluded the 60 patients recruitment for the clinic..
Bukwang Pharmaceutical Co., Ltd. announced that they concluded 60 patients recru..
2021.01.28
R&D news | Bukwang registered composition patent for SOL-804 in Europe
- approved in Europe and Eurasia, Australia, Mexico- Phase 1 study will be condu..
2021.01.14
R&D news | Bukwang has been granted a patent for its antiviral agent, ..
- Efficacy against SARS-Cov-2- Application under Patent Cooperation Treaty (PCT)..
2020.08.12
R&D news | Bukwang’s antiviral drug, Levovir®, confirms antiviral effec..
Levovir demonstrated comparable efficacy to KALETRA® against coronavirus in vitr..
2020.03.10
1
2
3
4
5